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December 20121824 Abstractsconfidence interval, 0.203-0.802; P  .01). Treatment with anakinra start-
ing 3 or 7 days after elastase exposure significantly reduced aortic dilation
compared with vehicle alone. Treatment starting 3 days after elastase re-
sulted in 43.7% 8.3% dilation vs 86.4% 3.5% dilation with vehicle alone
(P  .0005). Anakinra treatment starting 7 days after elastase exposure
reduced aortic dilation from 82.4%  6.9% with vehicle alone to 52.9% 
1.4% (P  .005). Aortas treated with anakinra demonstrated less macro-
phage and neutrophil infiltration, less elastin degradation, and less IL-1.
Conclusions: IL-1 signaling was critical for AAA formation, and
inhibition of its corresponding receptor through receptor antagonism with
anakinra attenuated AAA formation, macrophage and neutrophil infiltra-
tion, and elastin degradation. Furthermore, delayed initiation of IL-1R
antagonism after early aneurysm formation inhibited AAA progression,
suggesting that IL-1 pathway antagonism may function as a novel treat-
ment strategy for AAAs.
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School of Medicine, Pittsburgh, Pa
Introduction: Intimal hyperplasia is an overactive healing response
that leads to failure of half of all vascular interventions in 5 years. Increas-
ing evidence suggests that circulating progenitor cells expressing the marker
CD34 play an important role in this disease. Several studies have highlighted
either a direct cellular contribution to intimal lesions or by fostering a
favorable environment for restenosis. Despite their evolving importance in
this clinically important disease, the kinetics of CD34 cell mobilization after
vascular injury are not known. In addition, there is no way to specifically
intervene on these cells. In this study, we investigated the timecourse of
CD34-positive progenitor cells after vascular injury and examined whether
an affinity pheresis approach could mediate systemic depletion of CD34-
positive cells at the time of vascular injury in a large-animal model.
Methods: An ovine model underwent placement of an arteriovenous
polytetrafluorethylene graft between the carotid and jugular veins. The
contralateral carotid underwent balloon angioplasty. Endothelial injury in
this model was confirmed by scanning electron microscopy. The first groups
of animals underwent flow cytometric assessment of CD34/vascular endo-
thelial factor receptor 2-positive cells after vascular (n  3) and a control,
nonvascular surgery (n  3). Next, separate groups underwent vascular
injury, and over 14 days, the model underwent serial depletion using affinity
pheresis toward the progenitor cell marker CD34 (n 3) or a mock control
(n  4). Cells bound to the affinity system were eluted enzymatically and
examined by flow cytometry. Finally, complete blood counts were compared
between the study groups for changes after affinity pheresis.
Results: Our findings suggest a surge of CD34-positive cells after
vascular intervention that is not observed after control surgical procedures
(Fig 1). Our pheresis group revealed that the surge can be attenuated by a
CD34 affinity pheresis but not by a mock control (Fig 2). Consistent with
these findings, cells recovered from the affinity cartridge revealed large
numbers of CD34-positive cells that were not found in the control group.
Finally, our findings revealed that even after multiple sessions with an affinity
pheresis device, complete blood counts remain essentially unchanged.Fig.Conclusions: This study is the first to document a surge of CD34-
ositive progenitors that appears to be limited to macrovascular injury. This
nding may have important implications on the pathology of vascular
estenosis. We further conclude that CD34 affinity pheresis can mediate
ignificant in vivo depletion of circulating progenitor cells. Our results also
ndicate that the specificity of this depletion has minimal impact on clinical
easures of blood composition. Given the evolving role of these cells in the
athology of restenosis, this approach may have important clinical implica-
ions. Future studies will evaluate the implications of this depletion on
ecurrent vascular disease.
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Introduction: Paraplegia persists after thoracoabdominal aortic inter-
entions despite investigation into preventative pharmacologic adjuncts.
he 
-2a adrenergic receptor agonist, dexmedetomidine, has been shown to
reserve neurologic function and neuronal viability in a murine model of
pinal cord ischemia–reperfusion, although the mechanism remains elusive.
e hypothesize that dexmedetomidine will blunt the inflammation of
eperfusion effects in vivo after thoracic aortic occlusion with in vitro
emonstration of microglial inhibition via blunted Toll-like receptor (TLR)
signaling
Methods: Adult male C57BL/6 mice underwent 4 minutes of aortic
cclusion. Treatment groups received 25 g/kg dexmedetomidine at rep-
rfusion and at 12-hour intervals postprocedurally. Functional scoring was
one at 6 hours after surgery and at 12-hour intervals until 60 hours, when
pinal cords were removed and examined for neuronal viability and cytokine
roduction. Spinal cords from identical mice were removed for microglial
solation culture. Cells were grown to confluence and stimulated with the
LR-4 agonist LPS 10 ng/mL in presence of dexmedetomidine or vehicle
ontrol. Media was then removed for cytokine analysis. All treatment groups
ere compared with ischemic controls and significance determined by P 
05.
Results: Dexmedetomidine treatment significantly preserved neuro-
ogic function, cytoarchitecture, and neuronal viability in the murine spinal
ord. Treatment was associated with significantly reduced IL-6 production
t 6 and 60 hours. Microglial cells stimulated with LPS had production of
roinflammatory cytokines tumor necrosis factor-
 and interleukin-6, which
as significantly attenuated with treatment of dexmedetomidine.
Conclusions: The 
-2a agonist, dexmedetomidine, preserved neu-
ologic function and attenuated proinflammatory cytokine production in
n vivo and in vitro murine models. Furthermore, this relationship
ppears to occur through interruption of TLR-4–mediated microglial
ctivation and cytokine production. This involvement of TLR-4 signal-
ng in dexmedetomidine protection provides an insight into the mecha-
ism of paralysis after thoracic aortic interventions to guide future
harmacologic targets for attenuating spinal cord ischemia and reperfu-
ion injury.
Fig 1.
